Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 13Triple Negative Breast Neoplasms 7Prostatic Neoplasms 7Neoplasms 6Ovarian Neoplasms 4Neoplasm Metastasis 4Endometrial Neoplasms 2Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Prostatic Diseases 1Prostate Cancer Metastatic 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Pheochromocytoma 1Pathologic Complete Response 1Paraganglioma 1Pancreatic Neoplasms 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Hemangiosarcoma 1Glioma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Oxaliplatin 67Capecitabine 60Fluorouracil 58Bevacizumab 54Gemcitabine 51Paclitaxel 50Leucovorin 50Irinotecan 40Docetaxel 39Carboplatin 39Cisplatin 38pembrolizumab 37Nivolumab 37Cetuximab 35Sunitinib 25Trastuzumab 24Radiosurgery 24Radiotherapy 21Doxorubicin 21Cyclophosphamide 21Panitumumab 20Drug Therapy 19Pemetrexed 18Everolimus 18Sorafenib 17Interleukin-2 16Fulvestrant 16Albumin-Bound Paclitaxel 16atezolizumab 15Erlotinib Hydrochloride 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Metastasis × talazoparib × Clear all
NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute (NCI)

Phase 2 Recruiting
36 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT05327010 2026-05-13

Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
88 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02286687 2026-01-02

Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
150 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT04187833 2025-01-14

Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

Case Comprehensive Cancer Center

Phase 2 Completed
8 enrolled 12 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡